Dr. Janjigian shares why MATTERHORN was picked for the plenary and how its findings build on past studies in G/GEJ cancer.
Esophageal
Advertisement
Dr. Pietrantonio discusses how the benefits of T-DXd can potentially reshape the current treatment algorithm.
In the first-line HER2+ G/GEJ cancer, combinations of DV, toripalimab, and chemo produce high ORRs and promising early PFS.
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
We recently spoke with expert clinicians about the rapidly changing treatment landscape in upper gastrointestinal cancers.
Dr. Kelly discusses the first overall survival results from CheckMate 577 and how they compare to previous DFS results.
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Pembro plus lenvatinib with chemo may improve progression-free survival in patients when compared with the standard of care.
Researchers define characteristics of e-GISTS and determine whether endoscopic resection is a treatment option for patients.
Palliative EBRT can reduce physician-evaluated and patient-reported dysphagia symptoms in patients with incurable disease.
Pembrolizumab previously received accelerated approval for this indication in 2021 based on interim results from KEYNOTE-811.
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.